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Summary The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay
and rodent bone-marrow micronucleus and metaphase assays.
Razoxane (up to 5000 ug/plate) did not cause an increase in the mutation frequency in the
Salmonella/microsome assay. In the mouse micronucleus assay razoxane (200 and 400mgkg-1 i.p.) was
cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated
polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value). In the
Chinese hamster metaphase assay razoxane (up to 500mgkg-1 orally) induced abnormal chromosome
condensation and an increase in structural chromosome aberrations (7 fold compared to control value) as well
as an increase in the number ofpolyploid cells (8-fold compared to control value).
The mutagenic effect of razoxane was restricted to eukaryotic organisms and was associated with specific
chromosomal changes.
The bisdioxopiperazines are a class of antitumour
agents first synthesised at the Imperial Cancer
Research Fund as potential intracellularly activated
chelating agents (Creighton, 1970). The best known
of these is ICRF 159 which was shown to be active
against experimental tumours in rats and mice
(Creighton et al., 1969). It was subsequently devel-
oped as a drug for the treatment of certain forms
of human cancer under the approved name of
razoxane (Bakowski, 1976).
The effects of razoxane on both cells in culture
and tumours in vivo have been studied extensively.
Abnormal chromosome condensation and inhi-
bition of cell division were demonstrated by Sharpe
et al. (1970) using cultured human lymphocytes, but
only when razoxane was present at the G2/M stage
ofthe cell cycle. This cell cycle stage specificity ofthe
cytotoxic action of razoxane (as well as abnormal
mitosis and increase in cellular DNA content) has
also been demonstrated by Creighton (1979).
However, binding studies using radiolabelled
razoxane have failed to show an association with
any cellular macromolecules. In limited genetic tox-
icity assays razoxane has been reported to be non-
mutagenic in the Salmonella/microsome assay
(McCann et al., 1975) but causing an increase in
the mutation frequency of cultured Chinese hamster
V-79A cells as well as an increase in unscheduled
DNA synthesis (Witiak et al., 1979).
In this paperthemutagenic activity ofrazoxane has
been examined both in vitro (using the Salmonella/
microsome gene mutation assay) and in vivo (using
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rodent bone-marrow cells for metaphase and micro-
nucleus analysis).
Materials and methods
Chemicals
Razoxane was supplied by Imperial Chemical
Industries PLC, Pharmaceuticals Division. In the
Salmonella/microsome assay it was formulated in
dimethylsulphoxide (DMSO). In the in vivo meta-
phase and micronucleus assays, it was formulated
as ball-milled (overnight) suspensions in 0.5% w/v
aqueous polysorbate 80 ('Tween 80', Atlas Chem-
icals UK). Cyclophosphamide, N-methyl-N'nitro-N-
nitrosoguanidine and 2-acetylaminofluorene were
supplied by Koch Light Laboratories. Methotrexate,
daunomycin and 2-aminoanthracene were supplied
by Sigma Chemicals; 2-nitrofluorene and methyl
methanesulphonate by Aldrich Chemicals and
Neutral Red by Raymond Lamb.
Animals
The mice and Chinese hamsters (Cricetulus griseus)
were supplied by the Animal Breeding Unit, ICI.
The mice used were CCB F1 hybrids (BALB/c& x
CBA/Ca Y aged 10-12 weeks and weighed 15-
30g. The Chinese hamsters were aged 10-11 weeks
and weighed 20-33g.
Salmonella/microsome assay
The procedure followed that of Ames et al. (1975).
The S-9 mix was prepared from the liver of male
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Alderley Park Wistar derived rats (Alpk/AP) dosed
with Aroclor 1254, 500mgkg-1 (i.p), 5 days prior
to use. The amount of S-9 fraction per 1 ml of S-9
mix was 0.3ml and the S-9 mix was used at a
volume of 0.1 ml per plate. The maximum dose of
razoxane was determined by the solubility of the
compound. After treatment, plates were incubated
for 2 days at 37°C. Triplicate plates were prepared
for each treatment. The revertant colonies were
counted on an automatic colony counter.
Micronucleus assay
Doses of 200 and 400 mgkg 1 razoxane (equivalent
to 40% and 80% respectively, of the i.p. lethal
dose) were administered to male and female CCB F
mice as single i.p. injections. Aqueous polysorbate
80 (0.5%w/v; 10mlkg-1) and cyclophosphamide
(40 mgkg-1) were used as the vehicle and reference
positive control respectively. Animals were killed by
cervical dislocation 24, 48 and 72h after dosing
(4/sex/group/sample time). One femur from each
animal was removed and the bone marrow cavity
exposed. Three to four smears of bonemarrow were
made across a clean, grease-free microscope slide
using a paintbrush (Windsor & Newton No. 1)
lightly moistened in physiological saline. The slides
were air-dried and stained using Wrights stain. The
slides were coded prior to microscopic analysis. The
number of micronuclei in 500 polychromatic eryth-
rocytes (PCEs) was determined on each slide. The
ratio of PCEs to normochromatic erythrocytes
(NCEs) were also determined; as the first 200 PCEs
on each slide were counted the number of NCEs
seen in the same field of view was recorded. This
was used as an indicator ofcytotoxicity.
The data were analysed using two methods: (i)
assuming a Poisson distribution and (ii) Fishers
exact test for 2 x 2 tables. Comparisons between the
sexes within each group were made using a 2-sided
significance level.
Metaphase assay
This was divided into a time-course study (to
establish the time of maximal chromosome damge)
and a dose-response study (at the time of maximal
chromosome damage).
Time-course study Chinese hamsters (4 males/
sample time) were administered a single oral dose
of 500mgkg-1 body weight razoxane (the maxi-
mum tolerated oral dose). Aqueous polysorbate 80
(0.5% w/v; 10mlkg-1 bodyweight) was used as the
vehicle control and cyclophosphamide (40mgkg-1)
and methotrexate (500mgkg-1) were the reference
positive controls (2 males/group/sample time). At 6,
12, 24 and 48 h after dosing bone-marrow cell
chromosome preparations were made using the
method of Schmid et al. (1971). The chromosome
preparations were stained using 4% Giemsa (Gurrs
R66) for 2min. The slides were then mounted in
DPX and coded before microscopic analysis. Where
possible 50 cells at the metaphase stage of the cell
cycle were analysed for structural chromosome
damage from each animal.
Dose-response study Chinese hamsters (5/sex-
/group) were administered single oral doses of 20,
50, 100 or 500mgkg-1 razoxane. Aqueous polysor-
bate 80 (0.5%w/v; 10mlkg-1) was used as the
vehicle control. Chromosome preparations from
bone-marrow cells were made 24h after dosing (the
time of maximal chromosome damage - see results
section) as described above.
Statistical analysis was done using Fisher's exact
test (single-sided significance levels) and was re-
stricted to the dose-response study due to the small
group size in the time-course study. The incidence
of chromosomally aberrant cells and polyploid cells
in the razoxane-dosed animals was compared to
that of the vehicle control.
Results
Salmonella/microsome assay
The mean revertant colony counts for each of the
strains of Salmonella treated with razoxane are
shown in Table I. These counts were similar in the
presence and absence of S-9 to those of the appro-
priate untreated and solvent treated controls. All
the positive and negative control data were within
the historical and acceptable values for this
laboratory.
Micronucleus assay
The incidence of micronuclei for each group is
shown in Table II. Only data from the 24h sample
time were analysed statistically due to cytoxicity at
48 and 72h. At the 48 and 72h sample times there
were no deaths but there were large increases in the
number of NCEs and a correspondingly large de-
crease in the number of PCEs in the bone-marrow
of the razoxane-dosed animals which compromised
an accurate micronucleus analysis (see Table II).
At the 24h sample time, the incidence of micro-
nucleated PCEs was increased in the razoxane-
dosed animals (15/4000 PCEs at 200mgkg-1 and
9/4000 PCEs at 400mgkg-1 razoxane) compared
to the vehicle control (3/4000PCEs); the increase
was only statistically significant in animals dosed
200mgkg-1. In the limited data available at the
48h sample time there was an apparent increaseMUTAGENICITY OF RAZOXANE 727
Table la Results of the Salmonell/microsome assay in the absence of S9-mean number ofcolonies per plate
Strain ofSalmonela typhimurium
Amount per
Chemical plate (jig) TA 1535 TA 1537 TA 1538 TA 98 TA 100
Untreated 4.3+ 1.5 6.0+3.5 3.7+ 1.5 8.7+4.5 56.3+6.1
DMSO 100jil 4.3+ 1.2 4.0+1.7 2.3+0.6 9.0+4.6 59.7+5.5
Razoxane 10 8.0+ 1.7 4.0+2.6 2.0+ 1.0 7.0+ 1.7 58.3+4.2
50 5.3+0.6 3.7+0.6 2.7+1.5 6.7+1.2 63.7+3.2
200 4.7+2.5 8.0+0.0 2.0+1.0 7.3+0.6 61.7+3.5
1000 11.3+2.3 3.3+0.6 3.3+2.3 6.7+1.2 57.7+4.5
5000 7.3+1.2 2.7+0.6 2.7+1.2 7.0+2.0 53.7+2.1
N-Methyl-N'-nitro-N-
nitroso-guanidine 10 1278.0+320.7
Cyclophosphamide 500 24.7+4.0 + +
Neutral red 10 4.7+1.5
2-Nitro-fluorene 10 472.3+41.2
2-Acetylamino-fluorene 50 4.3+1.2
Methyl methane-sulphonate 670 370.0+23.4
2-Amino-anthracene 2 7.7+2.3 5.47+4.0
Results are the mean+s.d. of triplicate plates.
Table Ib: Results of the Salmonella/microsome assay in the presence of S9 - mean number ofcolonies per plate
Strain ofslamonella typhimurium
Amount per TA 1535 TA 1537 TA 1538 TA 98 TA 100
Chemical plate (uig) +S-9 +S-9 +S-9 +S-9 +S-9
Untreated - 8.3+2.1 3.3+0.6 7.0+ 1.7 13.0+4.4 64.0+12.5
DMSO OOjPI 9.0+1.0 6.0+0.0 9.3+2.5 15.0±4.6 62.3+3.2
Razoxane 10 5.7+1.5 4.7+2.1 5.7+1.2 9.3+2.9 66.0+1.0
50 8.7+2.3 4.3+2.1 6.3+4.0 7.3+2.3 70.3+6.8
200 6.0+4.4 4.0+ 1.0 9.0+2.6 12.0+ 1.0 60.0+4.0
1000 8.3+1.5 5.3+2.3 6.3+2.3 11.3+1.2 64.0+5.3
5000 8.7+5.1 6.3+3.2 6.3+3.2 11.3+3.1 60.7+3.8
Cyclophosphamide 500 214.7+62.6
Neutral red 10 80.7+5.5
2-Acetylamino-fluorene 50 780.0+ 129.6
2-Amino-anthracene 2 487.0±99.9 409.0+ 56.3
Daunomycin 5 117.7+31.8
Results are the mean+s.d. oftriplicate plates.728 R. ALBANESE & P.A. WATKINS
Table II Incidence of micronuclei in bone marrow poly-
chromatic erythrocytes of the CCB Fl mouse 24, 48 and
72h after a single i.p. dose of razoxane
Incidence of micronuclei in
4000 PCEs
(and PCE:NCE ratio)
Time after dosing
Compound (dose) (h)
24 48 72
Vehicle control
0.5% w/v aqueous
polysorbate 80
(lOmlkg-1) 3 (0.9) 3 (0.9) 2 (0.9)
Razoxane
(200mgkg 1) 15* (0.7) 2a (<0.2) ob (ND)
Razoxane
(400mgkg-1) 9 (0.6) 7c (<0.2) ND (ND)
Cyclophosphamide
40mgkg 1 29* (0.9) 21* (0.6) 0 (0.7)
Results are the number of micronuclei per 4000 PCEs
derived from 8 animals (4,3 and 4y) per group per sample
time. Numbers in parenthesis are the group mean
PCE:NCE ratio. Cytotoxicity limited analysis in the
following:
aonly 2/8 animals scored; 610 PCEs scored; bonly 1/8
animals scored; 178 PCEs scored; Conly 3/8 animals
scored; 714 PCEs scored; ND= Not determined due to
insufficient PCEs in bone-marrow preparations;
*Statistically significantly increase compared to control
(P<0.01). Data from razoxane dosed animals at 48 and
72h was not analysed statistically.
in the incidence of micronucleated PCEs at
400mgkg-1 razoxane (see Table II).
Cyclophosphamide caused the expected increase
in micronucleated PCEs at the 24 and 48h sample
times.
Metaphase assay
The results of the time course study and the dose-
response study are summarised in Tables III and IV
respectively.
Time-course study Six hours after dosing, the
bone-marrow cells of the razoxane-dosed animals
had abnormally condensed chromosomes (ACC).
The chromosomes were elongated and had the
appearance of early prophase chromsomes making
an accurate assessment of structural damage dif-
ficult (see Figure 1). At 12 and 24h chromosome
condensation was normal but the incidence of
chromosomally aberrant cells in the razoxane-dosed
animals was increased (maximum 14.0%) compared
to the vehicle control (1.4%). Maximal structural
Figure 1 (a) Normally condensed Chinese hamster
metaphase chromosomes and (b) abnormally
condensed chromosomes 6h after dosing razoxane.
chromosome damage was observed between 12 and
24h after dosing (see Table III and Figure 2).
There was a large increase in polyploid cells in the
razoxane-dosed group at the 24h sample time only
(16.5% incidence). At 6, 12 and 48h the incidence
of polyploid cells (range 0-2.5%) in the razoxane-
dosed group was within the historical control range
for this laboratory (0-5.3%). Based on these ob-
servations a single sample time, 24h after dosing
was chosen for the dose-response study.
a
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Table III Metaphase assay (time-course study). Numbers of cells containing structural chromosome aberrations
(2Sgroup/sample time except razoxane dosed animals where the results are from 4d/group/sample time)
No. ofcells with
Time after No. of
dosing Compound cells Multiple
(h) (and dose) analysed Gaps Breaks Fragments Exchanges Deletions damageb Polyploidy
Polysorbate
80 (lOmlkg-') 100 1 0 1 0 0 0 0
Razoxane
(500mgkg 1) 200a
6 Cyclophos-
phamide
(I50mgkg') 100 0 0 1 0 0 0 1
Methotrexate
(SOOmgkg ') 100 1 1 2 0 0 0 1
Polysorbate 80
(lOmlkg-') 100 0 0 0 0 0 0 1
Razoxane
(500mgkg1) 200 11 3 8 3 3 0 3
12 Cyclophos-
phamide
(l5Omgkg') 100 2 1 9 1 0 2 1
Methotrexate
(S00mgkg'-) 100 2 1 0 1 0 0 1
Polysorbate 80
(lOmlkg-1) 100 0 0 0 0 0 0 1
Razoxane
(500mgkg) 200 8 2 6 3 2 3 33
24 Cyclophos-
phamide
(l5Omgkg-1) 100 3 1 7 1 0 5 1
Methotrexate
(500mgkg-') 100 5 0 2 0 0 0 3
Polysorbate 80
(10mlkg-1) 100 2 0 0 0 0 0 0
Razoxane
(500mgkg1) 200 1 0 2 1 3 0 5
48 Cyclophos-
phamide
(lSOmgkg1) 100 0 0 0 1 1 0 0
Methotrexate
(500mgkg1) 100 2 0 1 1 2 0 0
'All cells contained abnormally condensed chromosomes.
bGreater than 10 structural aberrations in one cell.
An accurate assessment of structural damge was not possible;730 R. ALBANESE & P.A. WATKINS
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Figure 2 Structural chromosome damage (arrowed) in
razoxane-dosed animals.
Dose-response study The incidence of chromosom-
ally aberrant cells in the 100 and 500 mgkg- 1
razoxane-dosed groups was statistically significantly
increased (in a dose-dependent manner) compared
to the vehicle control (see Table IV). At the lower
doses (20 and 50 mgkg-1 razoxane), the incidence
of aberrant cells was similar to the vehicle control
but the types of damage (translocations and
deletions) observed were different from the vehicle
control and considered to be of biological sig-
nificance (see Table IV). There was also a dose-
dependent, statistically significant increase in poly-
ploid cells in the razoxane-dosed groups (range 2.2-
14.9%) compared to the vehicle control (0.4%).
The incidence of polyploid cells in the 20 and
50mgkg- 1 razoxane-dosed groups (2.2 and 2.4%
respectively) was within the historical control range
for this laboratory (0-3.5%).
Discussion
Razoxane was without effect in the Salmonella/mic-
rosome assay and mutagenic in mammalian
chromosomal assays. Razoxane has previously been
shown to induce both gene mutations and an
increase in unscheduled DNA synthesis irk cultured
mammalian cells (Witiak et al., 1977). The com-
bined data indicate that the mutagenic activity of
razoxane is restricted to eukaryotes. The molecular
mechanism by which razoxane is able to induce
these aberrations in DNA remains unknown.
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Dawson (1975) failed to detect covalent binding of
radio-labelled razoxane to cellular DNA or RNA,
but the damage to DNA may be indirect.
Livingstone et al. (1972) have shown that razoxane
is able to bind to histone proteins in vitro. Histones
are nucleoproteins which form an integral part of
the eukaryotic chromosome structure. If razoxane is
able to bind to histone proteins this association
could have an adverse effect on DNA synthesis
resulting in structural chromosome damage.
Razoxane also induces abnormal chromosome con-
densation and the effect appears to be unique to
razoxane since other anticancer agents which induce
structural chromosome aberrations (e.g. cyclo-
phosphamide and 5-fluorouracil) have no effect on
chromosome condensation. Razoxane was origin-
ally synthesised as an intracellularly active (metal
ion) chelating agent but this mode of action has
since been questioned (Huang et al., 1982). Chel-
ation could explain the abnormal chromosome con-
densation since metal ions (eg Ca2+) are known to
be involved in the complex chromosome condens-
ation process. Alternatively the razoxane/histone
association, demonstrated by Livingstone et al.
(1972), could also prevent normal chromosome
condensation by disrupting the DNA chain as it
begins to condense prior to mitosis. Chromosome
condensation occurs at the G2/M stage of the cell
cycle, the stage at which razoxane exerts its maxi-
mal cytotoxic effect (Sharpe et al., 1970; Creighton,
1974) and from these observations the mode of
action appears to be specific to condensing chroma-
tin of eukaryotes (NB prokaryotes do not undergo
a DNA condensation cycle).
Razoxane was also shown to affect cell division
as seen by the increase in polyploid cells. Similar
effects have been demonstrated in vitro using time-
lapse photography and cytofluorographic analysis
of razoxane treated L cells by Creighton (1979).
The time-lapse photography showed abnormal cell
division, i.e. as the daughter cells moved apart they
often remained linked by strands of nuclear
material. Eventually, the daughter cells rejoined to
form a tetraploid cell or separated with uneven
amounts of chromatin. The cytofluorographic ana-
lysis of the L-cells showed an increase in cellular
DNA content after treatment with razoxane.
The mechanism of action of razoxane is under
further investigation using closely related active and
inactive analogues of razoxane (Herman et al.,
1982) in cultured human lymphocytes.
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